Goodwin, Davis Polk Lead Roche's $4.8B Spark Buy
F. Hoffmann-La Roche AG is set to buy gene therapy company Spark Therapeutics Inc. in a $4.8 billion all-cash deal led by Goodwin Procter LLP and Davis Polk & Wardwell LLP, the...To view the full article, register now.
Already a subscriber? Click here to view full article